"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me ...

In this uncontrolled environment, the pathological cascade of Alzheimer’s begins, with the formation of beta-amyloid protein ...

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has ...

Few people in the UK with early stage Alzheimer's disease are likely to be suitable for the latest drugs which aim to halt progress of the condition, yet many are nevertheless likely to be referred ...

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

Lecanemab is a humanized mAb that binds with high affinity to soluble beta-amyloid protofibrils. 6 Its use was approved by the FDA in 2023, after publication of the results of the CLARITY AD clinical ...

The excitement generated by these drugs has been tinged, however, with a feeling that they were not much to show for decades of effort. The singular focus on amyloid was probably misplaced.

For decades, the theory that has dominated Alzheimer’s research, and drug pipelines, is known as the amyloid hypothesis ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, accessible and inexpensive than other existing tests.